Ernexa Therapeutics Inc.
ERNARating Trend
Earnings History
Next report: Mar 12, 2027 · EPS est. $-4.76| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $-1.89 | $-3.84 | — | — |
| Aug 6, 2026 | $-3.40 | $-3.30 | — | — |
| May 11, 2026 | $-6.95 | $-1.95 | — | — |
| Mar 13, 2026 | $-0.25 | — | — | — |
| Nov 7, 2025 | $-0.15 | $-33.00 | — | — |
| Aug 13, 2025 | $-0.61 | $-39.00 | — | — |
| May 7, 2025 | $-2.25 | $-48.00 | — | — |
| Mar 13, 2025 | $-48.00 | $-37.50 | $1.0K | — |
News
Leadership discusses recent FDA engagement, the technology underlying ERNA-101 and the development strategy supporting planned first-in-human clinical evaluation
Live video webcast with Sanjeev Luther, President and Chief Executive Officer; Dr. Christopher Rohde, developer of the technology underlying Ernexa's platform and member of Ernexa's Scientific Advisory Board; and Dr. Robert Pierce, Chief Scientific Officer, on Thursday, October 15th at 4:00 PM ET
Preclinical data highlighting ERNA-101's potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer Center in Houston Preclinical data highlighting ERNA-101's potential to activate the ovarian cancer tumor microenvironment and enhance checkpoint blockade will be presented October 6, 2026, at MD Anderson Cancer Center in Houston
CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no clinical pathology or histopathology findings; single-dose assessment showed no evidence of acute cytokine release
Ernexa selected for the Emerging Track, recognizing the Company among emerging innovators in the cell and gene therapy sector
Dr. Spiegel brings decades of global clinical development, regulatory and oncology leadership experience, including former Chief Medical Officer roles at Schering-Plough and PTC Therapeutics
ERNA-201 demonstrated encouraging disease-modifying activity in the industry-standard collagen-induced arthritis model, providing meaningful proof-of-concept for Ernexa's engineered synthetic iMSC platform beyond oncology
President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET Management available for one-on-one meetings with investors during the conference CAMBRIDGE, Mass.
Video webcast now available here
Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance